+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nordic Regulatory Affairs Market Size, Share & Trends Analysis Report by Service, by Service Provider, by Company Size, by Category, by Product Stage, by Indication, by End-use, by Country and Segment Forecasts, 2021 - 2028

  • ID: 5308292
  • Report
  • March 2021
  • Region: Denmark, Finland, Iceland, Norway, Sweden
  • 114 pages
  • Grand View Research

FEATURED COMPANIES

  • Freyr
  • GenPact Ltd.
  • ICON plc
  • Pharma Assist Sweden AB
  • PRA Health Sciences
  • Regsmart Lifesciences AB
Nordic Regulatory Affairs Market Growth & Trends

The Nordic regulatory affairs market size is expected to reach USD 272.7 million by 2028. It is expected to expand at a CAGR of 7.5% from 2021 to 2028. An increase in R&D activities in countries such as Denmark and Norway, drug pipeline, and clinical trial applications are some of the key factors expected to drive the market.

Denmark is the hub of R&D activities in Europe. The country is known for its long tradition for collaborative R&D and the fastest approval of clinical trials makes it a preferred destination to perform drug discovery and development. Denmark also has the largest commercial drug-development pipeline in Europe. Thus, the urge for a faster drug approval process is one of the key factors expected to drive the market in the country.

In Sweden, as stated by the SwedenBIO, around 148 companies have 420 drug development projects; an increase by 51 projects compared to 2016. In addition, around 6% of the total exports from Sweden are related to pharmaceuticals. Hence, this is projected to create demand for regulatory affairs services in the country.

The ongoing COVID-19 pandemic is expected to create the need for regulatory affairs in the Nordic countries. Countries such as Sweden and Denmark, which are the hub of clinical trials, are expected to witness an increase in demand for regulatory services as many of the trials are put on hold. In addition to this, due to COVID-19, a significant number of vaccines and drugs are in the development stage, which requires faster approval. This is possible only through clearance by regulatory bodies. Thus, the need for regulatory affairs is expected to increase in the Nordic countries.

Nordic Regulatory Affairs Market Report Highlights
  • By service, the regulatory writing and publishing segment led the market in 2020 owing to an increase in the outsourcing of selected regulatory functions by major life sciences companies.
  • Based on category, the medical devices segment held the largest share in 2020. The segment is driven by stiff competition owing to the increased demand for wearable devices.
  • Sweden dominated the market with a share of 59.6% in 2020 due to a rise in the number of drug development projects.
  • Changing regulatory landscape, increasing need for companies to focus on core business activities, and economic and competitive pressures are the main factors responsible for the market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Freyr
  • GenPact Ltd.
  • ICON plc
  • Pharma Assist Sweden AB
  • PRA Health Sciences
  • Regsmart Lifesciences AB
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Service
1.1.2. Service Provider
1.1.3. Company Size
1.1.4. Category
1.1.5. Product Stage
1.1.6. Indication
1.1.7. End Use
1.1.8. Country Scope
1.1.9. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the given 5 Nordic countries
1.9.2. Understanding market estimates and forecasts
1.9.3. Understanding attributes such as strategy framework and competitor categorization
1.9.4. Understanding the key service and application scopes to conclude on the market size

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Nordic Regulatory Affairs Market Variables, Trends & Scope
3.1. Penetration & Growth Prospect Mapping
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.2.3. Industry challenges
3.3. Nordic Regulatory Affairs Market Analysis Tools
3.3.1. Industry Analysis-Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Major Deals & Strategic Alliances Analysis
3.3.4. Market Entry Strategies

Chapter 4. Nordic Regulatory Affairs Market: Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Nordic Regulatory Affairs Market Share, 2020 & 2028
4.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
4.3.1. Regulatory consulting
4.3.2. Legal representation
4.3.3. Regulatory writing & publishing
4.3.4. Product registration & clinical trial applications
4.3.5. Other services

Chapter 5. Nordic Regulatory Affairs Market: Service Provider Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Nordic Regulatory Affairs Market Share, 2020 & 2028
5.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
5.3.1. In-house
5.3.2. Outsourcing

Chapter 6. Nordic Regulatory Affairs Market: Company Size Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Nordic Regulatory Affairs Market Share, 2020 & 2028
6.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
6.3.1. Small
6.3.2. Medium
6.3.3. Large

Chapter 7. Nordic Regulatory Affairs Market: Category Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Nordic Regulatory Affairs Market Share, 2020 & 2028
7.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
7.3.1. Drugs
7.3.2. Biologics
7.3.3. Medical Devices

Chapter 8. Nordic Regulatory Affairs Market: Product Stage Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Nordic Regulatory Affairs Market Share, 2020 & 2028
8.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
8.3.1. Preclinical
8.3.2. Clinical Studies
8.3.3. PMA

Chapter 9. Nordic Regulatory Affairs Market: Indication Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Nordic Regulatory Affairs Market Share, 2020 & 2028
9.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
9.3.1. Oncology
9.3.2. Neurology
9.3.3. Cardiology
9.3.4. Immunology
9.3.5. Others

Chapter 10. Nordic Regulatory Affairs Market: End-use Estimates & Trend Analysis
10.1. Segment Dashboard
10.2. Nordic Regulatory Affairs Market Share, 2020 & 2028
10.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
10.3.1. Medical Device Companies
10.3.2. Pharmaceutical Companies
10.3.3. Biotechnology Companies

Chapter 11. Nordic Regulatory Affairs Market: Country Estimates & Trend Analysis
11.1. Country Market Dashboard
11.2. Country Market Share Analysis, 2020 & 2028
11.3. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
11.3.1. Sweden
11.3.2. Norway
11.3.3. Denmark
11.3.4. Finland
11.3.5. Iceland

Chapter 12. Competitive Landscape
12.1. Recent Developments & Impact Analysis, By Key Market Participants
12.1.1. Pharma Assist Sweden AB
12.1.1.1. Company overview
12.1.1.2. Financial performance
12.1.1.3. Product benchmarking
12.1.1.4. Strategic initiatives
12.1.2. GenPact Ltd.
12.1.2.1. Company overview
12.1.2.2. Financial performance
12.1.2.3. Product benchmarking
12.1.2.4. Strategic initiatives
12.1.3. PRA Health Sciences
12.1.3.1. Company overview
12.1.3.2. Financial performance
12.1.3.3. Product benchmarking
12.1.3.4. Strategic initiatives
12.1.4. Charles River Laboratories International Inc.
12.1.4.1. Company overview
12.1.4.2. Financial performance
12.1.4.3. Product benchmarking
12.1.4.4. Strategic initiatives
12.1.5. ICON plc
12.1.5.1. Company overview
12.1.5.2. Financial performance
12.1.5.3. Product benchmarking
12.1.5.4. Strategic initiatives
12.1.6. Parexel International Corporation, Inc.
12.1.6.1. Company overview
12.1.6.2. Financial performance
12.1.6.3. Product benchmarking
12.1.6.4. Strategic initiatives
12.1.7. Freyr
12.1.7.1. Company overview
12.1.7.2. Financial performance
12.1.7.3. Product benchmarking
12.1.7.4. Strategic initiatives
12.1.8. Global Pharma Consultancy AB
12.1.8.1. Company overview
12.1.8.2. Financial performance
12.1.8.3. Product benchmarking
12.1.8.4. Strategic initiatives
12.1.9. Accell Clinical Research LLC
12.1.9.1. Company overview
12.1.9.2. Financial performance
12.1.9.3. Product benchmarking
12.1.9.4. Strategic initiatives
12.1.10. Regsmart Lifesciences AB
12.1.10.1. Company overview
12.1.10.2. Financial performance
12.1.10.3. Product benchmarking
12.1.10.4. Strategic initiatives


List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Nordic Regulatory Affairs Market, By Countries, 2016-2028 (USD Million)
Table 4 Nordic Regulatory Affairs Market, By Service, 2016-2028 (USD Million)
Table 5 Nordic Regulatory Affairs Market, By Service provider, 2016-2028 (USD Million)
Table 6 Nordic Regulatory Affairs Market, By Company size, 2016-2028 (USD Million)
Table 7 Nordic Regulatory Affairs Market, By Category, 2016-2028 (USD Million)
Table 8 Nordic Regulatory Affairs Market, By Drugs, 2016-2028 (USD Million)
Table 9 Nordic Regulatory Affairs Market, By Innovator, 2016-2028 (USD Million)
Table 10 Nordic Regulatory Affairs Market, By Generics, 2016-2028 (USD Million)
Table 11 Nordic Regulatory Affairs Market, By Biologics, 2016-2028 (USD Million)
Table 12 Nordic Regulatory Affairs Market, By Biotech, 2016-2028 (USD Million)
Table 13 Nordic Regulatory Affairs Market, By ATMP, 2016-2028 (USD Million)
Table 14 Nordic Regulatory Affairs Market, By Biosimilar, 2016-2028 (USD Million)
Table 15 Nordic Regulatory Affairs Market, By Medical Devices, 2016-2028 (USD Million)
Table 16 Nordic Regulatory Affairs Market, By Diagnostics, 2016-2028 (USD Million)
Table 17 Nordic Regulatory Affairs Market, By Therapeutics, 2016-2028 (USD Million)
Table 18 Nordic Regulatory Affairs Market, By Stage, 2016-2028 (USD Million)
Table 19 Nordic Regulatory Affairs Market, By Indication, 2016-2028 (USD Million)
Table 20 Nordic Regulatory Affairs Market, By End Use, 2016-2028 (USD Million)
Table 21 Sweden Regulatory Affairs Market, By Service, 2016-2028 (USD Million)
Table 22 Sweden Regulatory Affairs Market, By Service provider, 2016-2028 (USD Million)
Table 23 Sweden Regulatory Affairs Market, By Company size, 2016-2028 (USD Million)
Table 24 Sweden Regulatory Affairs Market, By Category, 2016-2028 (USD Million)
Table 25 Sweden Regulatory Affairs Market, By Drugs, 2016-2028 (USD Million)
Table 26 Sweden Regulatory Affairs Market, By Innovator, 2016-2028 (USD Million)
Table 27 Sweden Regulatory Affairs Market, By Generics, 2016-2028 (USD Million)
Table 28 Sweden Regulatory Affairs Market, By Biologics, 2016-2028 (USD Million)
Table 29 Sweden Regulatory Affairs Market, By Biotech, 2016-2028 (USD Million)
Table 30 Sweden Regulatory Affairs Market, By ATMP, 2016-2028 (USD Million)
Table 31 Sweden Regulatory Affairs Market, By Biosimilar, 2016-2028 (USD Million)
Table 32 Sweden Regulatory Affairs Market, By Medical Devices, 2016-2028 (USD Million)
Table 33 Sweden Regulatory Affairs Market, By Diagnostics, 2016-2028 (USD Million)
Table 34 Sweden Regulatory Affairs Market, By Therapeutics, 2016-2028 (USD Million)
Table 35 Sweden Regulatory Affairs Market, By Stage, 2016-2028 (USD Million)
Table 36 Sweden Regulatory Affairs Market, By Indication, 2016-2028 (USD Million)
Table 37 Sweden Regulatory Affairs Market, By End Use, 2016-2028 (USD Million)
Table 38 Norway Regulatory Affairs Market, By Service, 2016-2028 (USD Million)
Table 39 Norway Regulatory Affairs Market, By Service provider, 2016-2028 (USD Million)
Table 40 Norway Regulatory Affairs Market, By Company size, 2016-2028 (USD Million)
Table 41 Norway Regulatory Affairs Market, By Category, 2016-2028 (USD Million)
Table 42 Norway Regulatory Affairs Market, By Drugs, 2016-2028 (USD Million)
Table 43 Norway Regulatory Affairs Market, By Innovator, 2016-2028 (USD Million)
Table 44 Norway Regulatory Affairs Market, By Generics, 2016-2028 (USD Million)
Table 45 Norway Regulatory Affairs Market, By Biologics, 2016-2028 (USD Million)
Table 46 Norway Regulatory Affairs Market, By Biotech, 2016-2028 (USD Million)
Table 47 Norway Regulatory Affairs Market, By ATMP, 2016-2028 (USD Million)
Table 48 Norway Regulatory Affairs Market, By Biosimilar, 2016-2028 (USD Million)
Table 49 Norway Regulatory Affairs Market, By Medical Devices, 2016-2028 (USD Million)
Table 50 Norway Regulatory Affairs Market, By Diagnostics, 2016-2028 (USD Million)
Table 51 Norway Regulatory Affairs Market, By Therapeutics, 2016-2028 (USD Million)
Table 52 Norway Regulatory Affairs Market, By Stage, 2016-2028 (USD Million)
Table 53 Norway Regulatory Affairs Market, By Indication, 2016-2028 (USD Million)
Table 54 Norway Regulatory Affairs Market, By End Use, 2016-2028 (USD Million)
Table 55 Denmark Regulatory Affairs Market, By Service, 2016-2028 (USD Million)
Table 56 Denmark Regulatory Affairs Market, By Service provider, 2016-2028 (USD Million)
Table 57 Denmark Regulatory Affairs Market, By Company size, 2016-2028 (USD Million)
Table 58 Denmark Regulatory Affairs Market, By Category, 2016-2028 (USD Million)
Table 59 Denmark Regulatory Affairs Market, By Drugs, 2016-2028 (USD Million)
Table 60 Denmark Regulatory Affairs Market, By Innovator, 2016-2028 (USD Million)
Table 61 Denmark Regulatory Affairs Market, By Generics, 2016-2028 (USD Million)
Table 62 Denmark Regulatory Affairs Market, By Biologics, 2016-2028 (USD Million)
Table 63 Denmark Regulatory Affairs Market, By Biotech, 2016-2028 (USD Million)
Table 64 Denmark Regulatory Affairs Market, By ATMP, 2016-2028 (USD Million)
Table 65 Denmark Regulatory Affairs Market, By Biosimilar, 2016-2028 (USD Million)
Table 66 Denmark Regulatory Affairs Market, By Medical Devices, 2016-2028 (USD Million)
Table 67 Denmark Regulatory Affairs Market, By Diagnostics, 2016-2028 (USD Million)
Table 68 Denmark Regulatory Affairs Market, By Therapeutics, 2016-2028 (USD Million)
Table 69 Denmark Regulatory Affairs Market, By Stage, 2016-2028 (USD Million)
Table 70 Denmark Regulatory Affairs Market, By Indication, 2016-2028 (USD Million)
Table 71 Denmark Regulatory Affairs Market, By End Use, 2016-2028 (USD Million)
Table 72 Finland Regulatory Affairs Market, By Countries, 2016-2028 (USD Million)
Table 73 Finland Regulatory Affairs Market, By Service, 2016-2028 (USD Million)
Table 74 Finland Regulatory Affairs Market, By Service provider, 2016-2028 (USD Million)
Table 75 Finland Regulatory Affairs Market, By Company size, 2016-2028 (USD Million)
Table 76 Finland Regulatory Affairs Market, By Category, 2016-2028 (USD Million)
Table 77 Finland Regulatory Affairs Market, By Drugs, 2016-2028 (USD Million)
Table 78 Finland Regulatory Affairs Market, By Innovator, 2016-2028 (USD Million)
Table 79 Finland Regulatory Affairs Market, By Generics, 2016-2028 (USD Million)
Table 80 Finland Regulatory Affairs Market, By Biologics, 2016-2028 (USD Million)
Table 81 Finland Regulatory Affairs Market, By Biotech, 2016-2028 (USD Million)
Table 82 Finland Regulatory Affairs Market, By ATMP, 2016-2028 (USD Million)
Table 83 Finland Regulatory Affairs Market, By Biosimilar, 2016-2028 (USD Million)
Table 84 Finland Regulatory Affairs Market, By Medical Devices, 2016-2028 (USD Million)
Table 85 Finland Regulatory Affairs Market, By Diagnostics, 2016-2028 (USD Million)
Table 86 Finland Regulatory Affairs Market, By Therapeutics, 2016-2028 (USD Million)
Table 87 Finland Regulatory Affairs Market, By Stage, 2016-2028 (USD Million)
Table 88 Finland Regulatory Affairs Market, By Indication, 2016-2028 (USD Million)
Table 89 Finland Regulatory Affairs Market, By End Use, 2016-2028 (USD Million)
Table 90 Iceland Regulatory Affairs Market, By Service, 2016-2028 (USD Million)
Table 91 Iceland Regulatory Affairs Market, By Service provider, 2016-2028 (USD Million)
Table 92 Iceland Regulatory Affairs Market, By Company size, 2016-2028 (USD Million)
Table 93 Iceland Regulatory Affairs Market, By Category, 2016-2028 (USD Million)
Table 94 Iceland Regulatory Affairs Market, By Drugs, 2016-2028 (USD Million)
Table 95 Iceland Regulatory Affairs Market, By Innovator, 2016-2028 (USD Million)
Table 96 Iceland Regulatory Affairs Market, By Generics, 2016-2028 (USD Million)
Table 97 Iceland Regulatory Affairs Market, By Biologics, 2016-2028 (USD Million)
Table 98 Iceland Regulatory Affairs Market, By Biotech, 2016-2028 (USD Million)
Table 99 Iceland Regulatory Affairs Market, By ATMP, 2016-2028 (USD Million)
Table 100 Iceland Regulatory Affairs Market, By Biosimilar, 2016-2028 (USD Million)
Table 101 Iceland Regulatory Affairs Market, By Medical Devices, 2016-2028 (USD Million)
Table 102 Iceland Regulatory Affairs Market, By Diagnostics, 2016-2028 (USD Million)
Table 103 Iceland Regulatory Affairs Market, By Therapeutics, 2016-2028 (USD Million)
Table 104 Iceland Regulatory Affairs Market, By Stage, 2016-2028 (USD Million)
Table 105 Iceland Regulatory Affairs Market, By Indication, 2016-2028 (USD Million)
Table 106 Iceland Regulatory Affairs Market, By End Use, 2016-2028 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Nordic regulatory affairs market snapshot (2020)
Fig. 9 Nordic regulatory affairs market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Personalized medicine as a percentage of CDER approved novel molecules.
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 SWOT
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Nordic regulatory affairs market service outlook: Segment dashboard
Fig. 18 Nordic regulatory affairs market: service movement analysis
Fig. 19 Regulatory consulting market, 2016-2028 (USD Million)
Fig. 20 Legal representation market, 2016-2028 (USD Million)
Fig. 21 Regulatory writing and publishing market, 2016-2028 (USD Million)
Fig. 22 Product registration and clinical trial applications market, 2016-2028 (USD Million)
Fig. 23 Other regulatory services market, 2016-2028 (USD Million)
Fig. 24 Nordic regulatory affairs market service provider outlook: Segment dashboard
Fig. 25 Nordic regulatory affairs market: Service provider movement analysis
Fig. 26 In-house regulatory affairs market, 2016-2028 (USD Million)
Fig. 27 Outsourcing regulatory affairs market, 2016-2028 (USD Million)
Fig. 28 Nordic regulatory affairs market company size outlook: Segment dashboard
Fig. 29 Nordic regulatory affairs market: Company Size movement analysis
Fig. 30 Small-sized companies based regulatory affairs market, 2016-2028 (USD Million)
Fig. 31 Medium-sized companies based regulatory affairs market, 2016-2028 (USD Million)
Fig. 32 Large-sized companies based regulatory affairs market, 2016-2028 (USD Million)
Fig. 33 Nordic regulatory affairs market category outlook: Segment dashboard
Fig. 34 Nordic regulatory affairs market: Category movement analysis
Fig. 35 Drugs-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 36 Biologics-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 37 Medical devices-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 38 Nordic regulatory affairs product stage outlook: Segment dashboard
Fig. 39 Nordic regulatory affairs market: Product Stage movement analysis
Fig. 40 Preclinical-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 41 Clinical studies-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 42 PMA-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 43 Nordic regulatory affairs market indication outlook: Segment dashboard
Fig. 44 Nordic regulatory affairs market: indication movement analysis
Fig. 45 Oncology-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 46 Neurology-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 47 Cardiology-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 48 Immunology-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 49 Other indication-based regulatory affairs market, 2016-2028 (USD Million)
Fig. 50 Nordic regulatory affairs market end-use outlook: Segment dashboard
Fig. 51 Nordic regulatory affairs market: end-use movement analysis
Fig. 52 Medical device companies market, 2016-2028 (USD Million)
Fig. 53 Pharmaceutical companies market, 2016-2028 (USD Million)
Fig. 54 Biotechnology companies market, 2016-2028 (USD Million)
Fig. 55 Country outlook, 2020 & 2028
Fig. 56 Nordic market, 2016-2028 (USD Million)
Fig. 57 Norway market, 2016-2028 (USD Million)
Fig. 58 Denmark market, 2016-2028 (USD Million)
Fig. 59 Sweden market, 2016-2028 (USD Million)
Fig. 60 Iceland market, 2016-2028 (USD Million)
Fig. 61 Finland market, 2016-2028 (USD Million)
Fig. 62 Organization structure-RegSmart Life Science AB
Fig. 63 SWOT-RegSmart Life Science AB
Fig. 64 Organization structure-Pharm Assist Sweden AB
Fig. 65 SWOT-Pharm Assist Sweden AB
Fig. 66 Organization structure-Genpact
Fig. 67 SWOT-Genpact
Fig. 68 Organization structure-Charles River Laboratories International, Inc.
Fig. 69 SWOT-Charles River Laboratories International, Inc.
Fig. 70 Organization structure-ICON plc
Fig. 71 SWOT-ICON plc
Fig. 72 Organization structure-PAREXEL International Corporation
Fig. 73 SWOT-PAREXEL International Corporation
Fig. 74 Organization structure-Freyr
Fig. 75 SWOT-Freyr
Fig. 76 Organization structure-Accell Clinical Research, LLC
Fig. 77 SWOT-Accell Clinical Research, LLC
Fig. 78 Organization structure-PRA Health Sciences
Fig. 79 SWOT-PRA Health Sciences
Fig. 80 Organization structure-Global Pharma Consulting AB
Fig. 81 SWOT-Global Pharma Consulting AB
Note: Product cover images may vary from those shown
  • Pharma Assist Sweden AB
  • GenPact Ltd.
  • PRA Health Sciences
  • Charles River Laboratories International Inc.
  • ICON plc
  • Parexel International Corporation, Inc.
  • Freyr
  • Global Pharma Consultancy AB
  • Accell Clinical Research LLC
  • Regsmart Lifesciences AB
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll